Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations

BACKGROUND: Neoadjuvant treatment (NT) with chemotherapy (Ch) is a standard option for resectable stage III (N2) NSCLC. Several studies have suggested benefits with the addition of radiotherapy (RT) to NT Ch. The International Association for the Study of Lung Cancer (IASLC) published recommendation...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Guglielmetti, Diego, Sanchez-Lorente, David, Reyes, Roxana, Martinez, Daniel, Lucena, Carmen, Boada, Marc, Paredes, Pilar, Parera-Roig, Marta, Vollmer, Ivan, Mases, Joel, Martin-Deleon, Roberto, Castillo, Sergi, Benegas, Mariana, Muñoz, Silvia, Mayoral, Maria, Cases, Carla, Mollà, Meritxell, Casas, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641007/
https://www.ncbi.nlm.nih.gov/pubmed/34909399
http://dx.doi.org/10.5306/wjco.v12.i11.1047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641007/
https://www.ncbi.nlm.nih.gov/pubmed/34909399
http://dx.doi.org/10.5306/wjco.v12.i11.1047

Ejemplares similares